Skip to content
10-K

Annual Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-23-000156

← back to feed
Filed
Mar 30, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 30, 2023 7.88M sh
Capex FY 2022 · Dec 31, 2022 $39.16K
Capex FY 2022 · Dec 31, 2021 $292.53K
Operating Cash Flow FY 2022 · Dec 31, 2022 −$1.15M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$2.21M
Cash And Equivalents FY 2022 · Dec 31, 2022 $0
Cash And Equivalents FY 2022 · Dec 31, 2021 $192.48K
Stockholders Equity FY 2022 · Dec 31, 2022 −$3.14M
Stockholders Equity FY 2022 · Dec 31, 2021 −$1.38M
Current Liabilities FY 2022 · Dec 31, 2022 $4.97M
Current Liabilities FY 2022 · Dec 31, 2021 $3.05M
Total Liabilities FY 2022 · Dec 31, 2022 $5.4M
Total Liabilities FY 2022 · Dec 31, 2021 $3.58M
Current Assets FY 2022 · Dec 31, 2022 $233.19K
Current Assets FY 2022 · Dec 31, 2021 $419.16K
Total Assets FY 2022 · Dec 31, 2022 $2.25M
Total Assets FY 2022 · Dec 31, 2021 $2.2M
Eps Basic FY 2022 · Dec 31, 2022 −$0.23
Eps Basic FY 2022 · Dec 31, 2021 −$0.38
Sga Expense FY 2022 · Dec 31, 2022 $1.24M
Sga Expense restated FY 2022 · Dec 31, 2021 $2.14M
Gross Profit FY 2022 · Dec 31, 2022 $0
Gross Profit FY 2022 · Dec 31, 2021 $334
Cost Of Revenue FY 2022 · Dec 31, 2022 $0
Cost Of Revenue FY 2022 · Dec 31, 2021 $200
Revenue FY 2022 · Dec 31, 2022 $0
Revenue FY 2022 · Dec 31, 2021 $534